Terms: = Bone cancer AND HER1, YOR227W AND Treatment
10 results:
1. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract] [Full Text] [Related]
2. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
[TBL] [Abstract] [Full Text] [Related]
3. Lapatinib.
Voigtlaender M; Schneider-Merck T; Trepel M
Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
[TBL] [Abstract] [Full Text] [Related]
4. Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder cancer: EORTC Trial 30061.
Cerbone L; Sternberg CN; Sengeløv L; Agerbaek M; Van Herpen C; Marreaud S; Collette S; Zhang J; Daugaard G
Oncology; 2016; 90(1):21-8. PubMed ID: 26468947
[TBL] [Abstract] [Full Text] [Related]
5. Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer.
Stachnik A; Yuen T; Iqbal J; Sgobba M; Gupta Y; Lu P; Colaianni G; Ji Y; Zhu LL; Kim SM; Li J; Liu P; Izadmehr S; Sangodkar J; Scherer T; Mujtaba S; Galsky M; Gomez J; Epstein S; Buettner C; Bian Z; Zallone A; Aggarwal AK; Haider S; New MI; Sun L; Narla G; Zaidi M
Proc Natl Acad Sci U S A; 2014 Dec; 111(50):17995-8000. PubMed ID: 25453078
[TBL] [Abstract] [Full Text] [Related]
6. Human epidermal growth factor receptor bispecific ligand trap RB200: abrogation of collagen-induced arthritis in combination with tumour necrosis factor blockade.
Gompels LL; Malik NM; Madden L; Jin P; Feldmann M; Shepard HM; Paleolog EM
Arthritis Res Ther; 2011; 13(5):R161. PubMed ID: 21982514
[TBL] [Abstract] [Full Text] [Related]
7. A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens.
Ray-Coquard I; Le Cesne A; Whelan JS; Schoffski P; Bui BN; Verweij J; Marreaud S; van Glabbeke M; Hogendoorn P; Blay JY
Oncologist; 2008 Apr; 13(4):467-73. PubMed ID: 18448563
[TBL] [Abstract] [Full Text] [Related]
8. Acute and fatal diarrhoea after erlotinib plus abdominal palliative hypofractionated radiotherapy in a metastatic non-small cell lung cancer patient: a case report.
Silvano G; Lazzari G; Lovecchio M; Palazzo C
Lung Cancer; 2008 Aug; 61(2):270-3. PubMed ID: 18442870
[TBL] [Abstract] [Full Text] [Related]
9. [Molecular diagnostic and targeted therapy--"Barking dogs are going to bite": presentations from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta 2006].
Rody A; Loibl S; Kaufmann M
Zentralbl Gynakol; 2006 Oct; 128(5):233-41. PubMed ID: 17001557
[TBL] [Abstract] [Full Text] [Related]
10. Challenges in the endocrine management of breast cancer.
Mouridsen HT; Rose C; Brodie AH; Smith IE
Breast; 2003 Aug; 12 Suppl 2():S2-19. PubMed ID: 14659138
[TBL] [Abstract] [Full Text] [Related]